Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P41181 (
collecting duct
)
5,183
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Glycerophosphocholine (GPC) is an abundant osmoprotective renal medullary organic osmolyte. We previously found that its synthesis from phosphatidylcholine is catalyzed by tonicity-regulated activity of the phospholipase B, neuropathy target esterase. We also found that its degradation is catalyzed by glycerophosphocholine phosphodiesterase (GPC-PDE) activity and that elevating osmolality from 300 to 500 mosmol/kg by adding NaCl or urea, inhibits GPC-PDE activity, which contributes to the resultant increase of GPC. In the present studies we identify
GDPD5
(glycerophosphodiester phosphodiesterase domain containing 5) as a GPC-PDE that is rapidly inhibited by high NaCl or urea. Recombinant
GDPD5
colocalizes with neuropathy target esterase in the perinuclear region of HEK293 cells, and immuno-precipitated recombinant
GDPD5
degrades GPC in vitro. The in vitro activity is reduced when the cells from which the
GDPD5
is immuno-precipitated have been exposed to high NaCl or urea. In addition, high NaCl decreases mRNA abundance of
GDPD5
via an increase of its degradation rate, although high urea does not. At 300 mosmol/kg siRNA knockdown of
GDPD5
increases GPC in mouse inner medullary
collecting duct
-3 cells, and over expression of recombinant
GDPD5
increases cellular GPC-PDE activity, accompanied by decreased GPC. We conclude that
GDPD5
is a GPC-PDE that contributes to osmotic regulation of cellular GPC.
...
PMID:GDPD5 is a glycerophosphocholine phosphodiesterase that osmotically regulates the osmoprotective organic osmolyte GPC. 1866 93